enGene appoints Dr. Hussein Sweiti as CMO; former J&J bladder cancer lead

enGene Therapeutics Inc.

Dr. Sweiti appointed Chief Medical Officer effective September 29, 2025.
Previously Global Medical Head, Oncology at J&J; led bladder cancer portfolio and recent FDA NMIBC approval.
Will oversee global clinical development for detalimogene; BLA submission planned for 2H 2026.
Brings 15+ years experience in surgical oncology, drug development, and regulatory submissions.
Appointed after target enrollment reached in pivotal detalimogene NMIBC trial.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.